Xeris Biopharma Holdings Inc (NASDAQ: XERS) on Friday, soared 5.21% from the previous trading day, before settling in for the closing price of $7.3. Within the past 52 weeks, XERS’s price has moved between $2.48 and $7.61.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 40.01% over the past five years. The company achieved an average annual earnings per share of 91.89%. With a float of $149.81 million, this company’s outstanding shares have now reached $161.22 million.
Let’s look at the performance matrix of the company that is accounted for 394 employees. In terms of profitability, gross margin is 37.11%, operating margin of -3.99%, and the pretax margin is -14.36%.
Xeris Biopharma Holdings Inc (XERS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Xeris Biopharma Holdings Inc is 7.83%, while institutional ownership is 56.35%. The most recent insider transaction that took place on Aug 13 ’25, was worth 786,459. In this transaction Director of this company sold 107,500 shares at a rate of $7.32, taking the stock ownership to the 833,483 shares. Before that another transaction happened on Aug 12 ’25, when Company’s Director sold 42,500 for $7.28, making the entire transaction worth $309,226. This insider now owns 115,000 shares in total.
Xeris Biopharma Holdings Inc (XERS) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.06 earnings per share (EPS) for the period topping the consensus outlook (set at -0.08) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 91.89% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Xeris Biopharma Holdings Inc (XERS) is currently performing well based on its current performance indicators. A quick ratio of 1.24 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit 0.01 in the next quarter and is forecasted to reach 0.23 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Xeris Biopharma Holdings Inc (NASDAQ: XERS) saw its 5-day average volume 3.4 million, a positive change from its year-to-date volume of 2.58 million. As of the previous 9 days, the stock’s Stochastic %D was 91.07%.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 98.98%, which indicates a significant increase from 98.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.41 in the past 14 days, which was higher than the 0.28 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.22, while its 200-day Moving Average is $4.30. Nevertheless, the first resistance level for the watch stands at $7.86 in the near term. At $8.05, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.38. If the price goes on to break the first support level at $7.35, it is likely to go to the next support level at $7.02. The third support level lies at $6.84 if the price breaches the second support level.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
Market capitalization of the company is 1.24 billion based on 161,480K outstanding shares. Right now, sales total 203,070 K and income totals -54,840 K. The company made 71,540 K in profit during its latest quarter, and -1,930 K in sales during its previous quarter.
